For decades, the default response to a breast cancer diagnosis has been a blunt instrument: cut, burn, or poison. But a quiet revolution is unfolding in oncology labs—one that asks a radical question: what if we could know, with near-certainty, which patients will benefit from chemotherapy and which will not?
That question now has a powerful answer. A groundbreaking genomic test, known as the MammaPrint assay, has been shown to reliably identify which early-stage breast cancer patients can safely skip chemotherapy without compromising their survival odds. The findings, published in the New England Journal of Medicine in 2024, are based on the largest randomized trial of its kind—the MINDACT study—which followed nearly 6,700 women across nine countries for a median of 8.7 years.
“This is not just a refinement of treatment,” says Dr. Laura van ‘t Veer, a molecular biologist at the University of California, San Francisco, and co-lead of the MINDACT trial. “It is a paradigm shift. We are moving from a one-size-fits-all approach to a personalized risk assessment that spares women unnecessary toxicity.”
How the Genomic Test Works
Unlike standard tumor grading, which relies on a pathologist’s visual assessment of cell shape and division, MammaPrint analyzes the activity of 70 specific genes within a biopsy sample. The test produces a binary result—low risk or high risk—based on the tumor’s molecular signature.
In the MINDACT trial, women with early-stage, hormone-receptor-positive, HER2-negative breast cancer—the most common subtype—were categorized by both clinical risk (using traditional factors like tumor size and lymph node status) and genomic risk (using MammaPrint). Those with a high clinical risk but a low genomic risk were randomly assigned to receive chemotherapy or not.
The results were striking. Among the 1,550 women in this discordant group, the 5-year distant metastasis-free survival rate was 94.7% for those who received chemotherapy and 93.9% for those who did not—a difference of less than one percentage point. Statistically, that gap is negligible. In practical terms, it means that roughly 46% of women classified as high clinical risk could safely forgo chemotherapy.
“The difference was so small it’s clinically irrelevant,” explains Dr. Fatima Cardoso, director of the Breast Unit at the Champalimaud Clinical Centre in Lisbon and the trial’s lead author. “For the first time, we have level-one evidence that genomic testing can identify a large group of patients who derive no significant benefit from chemotherapy.”
Why This Matters for Millions of Patients
Breast cancer remains the most diagnosed cancer among women worldwide, with over 2.3 million new cases annually. Of these, roughly 60–70% are hormone-receptor-positive, HER2-negative tumors. Until now, many oncologists have defaulted to chemotherapy for patients with larger tumors or positive lymph nodes—even when the cancer appears biologically indolent.
Chemotherapy is brutal. Its side effects range from nausea and hair loss to long-term cardiac damage, cognitive impairment (commonly called “chemo brain”), and secondary leukemia. For patients who derive no survival benefit, these risks are unnecessary. The economic toll is also steep: a full course of chemotherapy can cost between $10,000 and $100,000 in the United States, depending on the regimen.
Dr. Anne Partridge, a breast oncologist at the Dana-Farber Cancer Institute in Boston, emphasizes the real-world impact. “I’ve had patients who spent months recovering from chemo, only to later learn their tumor was low-risk. This test gives us the confidence to say, ‘You don’t need this.’ That changes lives.”
MammaPrint is not the only genomic test on the market. The Oncotype DX test, which analyzes 21 genes, has been widely used in the United States for a decade. However, MammaPrint offers a broader genetic panel and has now demonstrated efficacy in a larger, more diverse international cohort. The U.S. Food and Drug Administration approved MammaPrint in 2007, but uptake has been slow due to cost—around $4,200 per test—and insurance coverage gaps.
Context: The History of Overtreatment in Oncology
The problem of overtreatment in breast cancer is not new. In the 1990s, clinical guidelines encouraged aggressive treatment for all but the smallest tumors, driven by the belief that any delay or omission might allow micrometastases to spread. That philosophy saved lives—but also led to millions of women receiving therapies they did not need.
A landmark 2015 study in the Journal of the American Medical Association estimated that up to 30% of breast cancer patients in the U.S. received chemotherapy that offered no survival benefit. The MINDACT trial provides a tool to cut that number dramatically.
“What we are seeing is the maturation of precision oncology,” says Dr. Carlos Caldas, a cancer geneticist at the University of Cambridge. “We have moved from treating all cancers alike to treating each cancer according to its molecular fingerprint. The MINDACT data cement the role of genomics in routine decision-making.”
Limitations and Next Steps
Despite the promise, the test has limitations. It has not been validated for triple-negative breast cancer or HER2-positive breast cancer—subtypes that are biologically more aggressive. Additionally, the MINDACT trial included mostly white women in Europe and North America; broader studies in African, Asian, and Latin American populations are needed to confirm generalizability.
Cost remains a barrier. In the U.S., Medicare and many private insurers cover MammaPrint for patients who meet eligibility criteria, but uninsured patients may struggle to access it. Advocacy groups are pushing for expanded coverage, especially in light of the new data.
“The evidence is now overwhelming,” concludes Dr. van ‘t Veer. “Genomic testing should become standard of care for every woman with early-stage hormone-receptor-positive breast cancer. We have the science. Now we need the will to implement it.”
Looking forward, researchers are developing next-generation blood-based genomic tests that could eliminate the need for tissue biopsy. These “liquid biopsies” would analyze circulating tumor DNA, potentially allowing for real-time monitoring of risk over time. Clinical trials are underway, with results expected within three to five years.
For patients facing a breast cancer diagnosis today, the message is clear: ask your oncologist about genomic testing. It could spell the difference between months of grueling treatment and a simple, targeted approach. The era of chemotherapy for all is ending. The era of precision is here.
